INmune Bio (NASDAQ:INMB – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect INmune Bio to post earnings of ($0.54) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
INmune Bio Stock Performance
Shares of NASDAQ:INMB opened at $8.86 on Wednesday. INmune Bio has a one year low of $4.32 and a one year high of $12.72. The stock has a market capitalization of $235.60 million, a price-to-earnings ratio of -4.06 and a beta of 1.93. The company has a 50-day simple moving average of $8.34 and a 200-day simple moving average of $6.35.
Wall Street Analysts Forecast Growth
INMB has been the topic of several analyst reports. Rodman & Renshaw initiated coverage on INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 target price on the stock. Maxim Group lifted their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, Scotiabank raised their target price on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, February 11th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, INmune Bio presently has a consensus rating of “Buy” and an average target price of $22.80.
INmune Bio Company Profile
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Featured Stories
- Five stocks we like better than INmune Bio
- What is the Hang Seng index?
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- Low PE Growth Stocks: Unlocking Investment Opportunities
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Stock Analyst Ratings and Canadian Analyst Ratings
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.
